Sino Biological Inc. Class A 301047

Partnership brings Monod Bio's LuxSit luciferase and NovoBodies to SignalChem Biotech's custom assay services Agreement expands Sino Biological's specialized CRO capabilities through integration of AI-enabled life science tools SEATTLE and RICHMOND...

Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced that its gene synthesis and cell-free protein expression workflow was used in a recent study by Tencent AI for Life Sciences Lab published in Nature Communications, enabling rapid validation of AI-designed proteins with improved activity, stability, and multifunctionality.

Ultra-Fast Protein/Antibody Synthesis in 3 Hours, Speed Up AI-Powered HTP Screening HOUSTON, TEXAS - May 18, 2026 (NEWMEDIAWIRE) - Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to anno...

The World Health Organization (WHO) has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has launched the 2026-2027 Northern Hemisphere influenza vaccine strain antigens to accelerate vaccine development.